NCT04898751View on ClinicalTrials.gov

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

CompletedOBSERVATIONAL

Enrollment

2,214

Participants

Timeline

Start Date

January 1, 2008

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions

Cutaneous Toxicity From ICI Therapy

Interventions

DRUG

Immune checkpoint inhibitor (ICI)

Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).

Trial Locations (1)

21215

Sidney Kimmel Comprehensive Care Center, Baltimore

All Listed Sponsors

lead

Johns Hopkins University

OTHER

NCT04898751 - Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter